Fangzhou Jianke

Fangzhou Jianke is a publicly listed company on the HKEX with ticker symbol 6086 in Hong Kong, operating in the Retail trade sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Fangzhou Jianke has successfully raised a total of $280M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $19.24 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Fangzhou Jianke operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 111 Group, Shanghai Pharmaceutical, 7LK, JD Health and Jingle fast medicine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.